A35R Protein Segmentation for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for modulating immune responses and treating poxvirus infections, autoimmune disorders, and transplant rejection, as well as enhancing vaccine efficacy, due to the immunomodulatory activity of the A35R protein in poxviruses.
Innovation Solution
Administration of A35R protein or its biologically active fragments, nucleic acids encoding the protein, and antibodies or inhibitors specific to the A35R protein to modulate immune responses, treat infections, and prevent autoimmune disorders and transplant rejection, while engineering poxviruses to lack A35R protein activity for vaccine enhancement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If A35R protein is administered to modulate immune response, then immune response modulation is achieved, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent segments the A35R protein into multiple biologically active fragments (e.g., amino acid residues 1-50, 51-100, 101-150, 151-192) that can be used independently or in combination. This segmentation allows for simplified treatment protocols where smaller, more manageable protein fragments can be administered instead of the full-length protein, reducing complexity while maintaining immunomodulatory efficacy.
Solution Approach 2:
The patent explores variations in the A35R protein sequence and structure to identify critical regions responsible for immunomodulatory activity. By changing parameters such as amino acid sequence, molecular weight, and structural conformation, the patent develops optimized versions of the protein that maintain or enhance therapeutic effect while potentially simplifying production and administration protocols.
2Reliability
If poxvirus is engineered to lack A35R protein activity for vaccine enhancement, then vaccine efficacy is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies the extraction principle by removing or inactivating the A35R gene from the poxvirus genome to create attenuated vaccine strains. This deletion or modification approach simplifies the manufacturing process compared to traditional methods requiring complex gene editing, as it relies on straightforward genetic engineering techniques that are well-established in poxvirus vaccine production. The resulting virus lacks the immunosuppressive A35R protein, thereby enhancing vaccine efficacy.
Data Source
AI summary
The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.